April 19th 2024
The primary endpoint of the study was clinical remission at week 52 with vedolizumab
FDA Approves Upadacitinib for Adults With Moderately to Severely Active Crohn Disease
May 18th 2023In clinical trials of patients with Crohn disease, upadacitinib demonstrated early and long-term symptom relief, as well a visible reduction of damage to the intestinal lining caused by excess inflammation.
Read More